Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1997-9-30
|
pubmed:abstractText |
A common complication in patients with breast or prostate cancer is bone metastases causing pain. New radionuclide therapy methods have recently been proposed for palliation, including 186Re-hydroxyethylidene diphosphonate (186Re-HEDP). This paper reports on the local development of 186Re-HEDP and the biodistribution studied in animals for eventual use in patients. Adult dose was computed assuming a 70 kg standard man. The 186Re was labelled to HEDP using standard techniques. The biodistribution in five Chacma baboons (Papio ursinus) was studied. Doses ranging from 39.4 to 44.9 MBq kg(-1) (mean 43.6 +/- 2.8 MBq kg[-1]) were administered, corresponding to an adult human dose of 2960 MBq (80 mCi). Whole-body images of the animals were obtained with a dual-headed scintillation camera on an hourly basis for 6 h post-injection and then daily for 3 days. The bone, soft tissue, kidneys and urinary bladder were considered source organs and data from these organs were used in a compartmental model to obtain the mean residence times of the radionuclide in the different source organs. Radiation dose estimates for 186Re-HEDP were subsequently obtained with the MIRDOSE 3 program. The estimated absorbed radiation doses to some of the organs (expressed in mGy MBq[-l]) were as follows: bone surface 1.69; kidneys 0.09; liver 0.04; ovaries 0.04; red marrow 0.75; total body 0.12; urinary bladder wall 0.43. 186Re-HEDP yielded an effective dose of 0.17 mSv MBq(-1). The radiation dose delivered to the bone marrow in this study did not cause any detrimental effect to the baboons, indicating that locally produced 186Re-HEDP is suitable for clinical use.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Etidronic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Rhenium,
http://linkedlifedata.com/resource/pubmed/chemical/rhenium-186 HEDP
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0143-3636
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
582-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9259533-Adult,
pubmed-meshheading:9259533-Animals,
pubmed-meshheading:9259533-Bone Neoplasms,
pubmed-meshheading:9259533-Bone and Bones,
pubmed-meshheading:9259533-Breast Neoplasms,
pubmed-meshheading:9259533-Etidronic Acid,
pubmed-meshheading:9259533-Female,
pubmed-meshheading:9259533-Humans,
pubmed-meshheading:9259533-Kidney,
pubmed-meshheading:9259533-Male,
pubmed-meshheading:9259533-Metabolic Clearance Rate,
pubmed-meshheading:9259533-Organometallic Compounds,
pubmed-meshheading:9259533-Palliative Care,
pubmed-meshheading:9259533-Papio,
pubmed-meshheading:9259533-Prostatic Neoplasms,
pubmed-meshheading:9259533-Radiopharmaceuticals,
pubmed-meshheading:9259533-Rhenium,
pubmed-meshheading:9259533-Tissue Distribution,
pubmed-meshheading:9259533-Urinary Bladder
|
pubmed:year |
1997
|
pubmed:articleTitle |
Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
|
pubmed:affiliation |
Department of Biophysics, University of the Orange Free State, Bloemfontein, South Africa.
|
pubmed:publicationType |
Journal Article
|